Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764316 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
A Phase 1 study, sponsored by Bayer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT06764316 is a Phase 1 study that is actively recruiting participants, run by Bayer. The registered enrollment target is 148 participants.
The verdict
NCT06764316, a Phase 1 study, is actively recruiting participants, sponsored by Bayer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans. Participants will take part in one of the 4 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Parts 3 and 4 of the study. During the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.
Interventions
- DRUG BAY 3547926
- DRUG BAY 3547922
- DRUG additional intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06764316
The ClinicalTrials.gov registry entry for NCT06764316 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BAY 3547926 is the first listed.
NCT06764316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06764316 about?
NCT06764316 is a clinical study titled "A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer". In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY ...
What is the current status of trial NCT06764316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2025-02-28. Estimated completion is 2031-08-31.
What interventions are being tested in trial NCT06764316?
The interventions under investigation include: BAY 3547926 (DRUG), BAY 3547922 (DRUG), additional intervention (DRUG).
Who is sponsoring clinical trial NCT06764316?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.